Stock Scorecard
Stock Summary for Genfit (GNFT) - $3.63 as of 4/18/2024 1:47:31 AM EST
Total Score
9 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for GNFT
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for GNFT
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for GNFT
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for GNFT
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for GNFT
Financial Details for GNFT
Company Overview |
|
---|---|
Ticker | GNFT |
Company Name | Genfit |
Country | USA |
Description | Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company is headquartered in Loos, France. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 3/31/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 3.63 |
Last Day Price Updated | 4/18/2024 1:47:31 AM EST |
Last Day Volume | 3,416 |
Average Daily Volume | 5,129 |
52-Week High | 4.75 |
52-Week Low | 2.89 |
Last Price to 52 Week Low | 25.61% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 63.13 |
Sector PE | 61.99 |
5-Year Average PE | 12.49 |
Free Cash Flow Ratio | 2.33 |
Industry Free Cash Flow Ratio | 19.02 |
Sector Free Cash Flow Ratio | 30.47 |
Current Ratio Most Recent Quarter | 2.94 |
Total Cash Per Share | 1.56 |
Book Value Per Share Most Recent Quarter | 1.37 |
Price to Book Ratio | 2.45 |
Industry Price to Book Ratio | 7.53 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 5.20 |
Industry Price to Sales Ratio Twelve Trailing Months | 10.02 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.19 |
Share Statistics |
|
Total Shares Outstanding | 49,861,000 |
Market Capitalization | 180,995,430 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -21.81% |
Reported EPS 12 Trailing Months | -0.62 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | 0.11 |
Net Income Twelve Trailing Months | -28,893,999 |
Net Income Past Year | -28,894,000 |
Net Income Prior Year | -23,720,000 |
Quarterly Revenue Growth YOY | 37.30% |
5-Year Revenue Growth | 233.73% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 77,789,000 |
Total Cash Past Year | 77,789,000 |
Total Cash Prior Year | 136,001,000 |
Net Cash Position Most Recent Quarter | 15,140,000 |
Net Cash Position Past Year | 20,344,000 |
Long Term Debt Past Year | 57,445,000 |
Long Term Debt Prior Year | 70,195,000 |
Total Debt Most Recent Quarter | 62,649,000 |
Equity to Debt Ratio Past Year | 0.54 |
Equity to Debt Ratio Most Recent Quarter | 0.52 |
Total Stockholder Equity Past Year | 67,421,000 |
Total Stockholder Equity Prior Year | 94,528,000 |
Total Stockholder Equity Most Recent Quarter | 67,421,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | False |
Liquidity Rating | None |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.02 |
MACD Signal | -0.02 |
20-Day Bollinger Lower Band | 3.36 |
20-Day Bollinger Middle Band | 3.68 |
20-Day Bollinger Upper Band | 3.99 |
Beta | 0.87 |
RSI | 45.42 |
50-Day SMA | 3.70 |
200-Day SMA | 4.12 |
System |
|
Modified | 4/18/2024 1:47:32 AM EST |